Lilly's Foundayo pill cut sleep apnea severity in two late-stage studies
In participants not using positive airway pressure (PAP) therapy, Foundayo cut the apnea-hypopnea index, a count of breathing interruptions per hour, by 21.1 events per hour, or 43.8%, compared with a 6.3% drop on placebo, Lilly said. In participants using PAP, the reduction was 18.3 events per hour, or 27.5%, compared with 3.0% on placebo. The two studies enrolled 363 and 349 people, and those taking Foundayo lost about 11% of their body weight, according to Lilly and CNBC.
The most common side effects were gastrointestinal, and about 12% of participants not using PAP stopped Foundayo because of side effects, compared with 3.8% on placebo, Lilly and CNBC reported. Lilly plans to submit the results to the FDA by the end of 2026.
Why it matters: Lilly's injectable Zepbound became the first medicine approved in the U.S. for obstructive sleep apnea in December 2024, CNBC noted. Lilly said the condition affects an estimated 936 million adults worldwide, most of whom have never been diagnosed.
References
- Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severityEli Lilly · investor.lilly.com · 2026-11-09
- Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA)JAMA · jamanetwork.com · 2026-11-09
- Eli Lilly's Foundayo obesity pill eases sleep apnea in late-stage trialCNBC · cnbc.com · 2026-11-09